文献速递间质性肺疾病

肌炎特异性抗体可识别具有独特表型的间质性肺炎伴自身免疫特征

Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype.
PubMed 文献 · Eur Respir J · 2020-12-03

这项多中心回顾性研究评估了269例符合IPAF标准的患者,其中35例(13%)携带肌炎特异性抗体(MSA),65例(24.2%)携带肌炎相关抗体(MAA)。MSA阳性IPAF患者的3年无移植生存率最高,接近特发性炎症性肌病相关ILD(IIM-ILD)患者;而MAA阳性与MAA/MSA阴性IPAF患者生存无差异。UIP形态与不同结局风险相关。作者建议将MSA从IPAF标准中移除,此类患者应按IIM-ILD管理。

要点

  • MSA阳性IPAF患者临床特征和结局与IIM-ILD相似,生存率最高。
  • MAA阳性与MAA/MSA阴性IPAF患者生存无差异。
  • UIP形态是IPAF患者结局的强预测因素。

核心结论

  • MSA而非MAA识别出独特的IPAF表型,其临床特征和结局与IIM-ILD相似。
  • UIP形态是符合IPAF标准的其他患者结局的强预测因素。
  • 建议将MSA从IPAF标准中移除,MSA阳性患者应按IIM-ILD管理。

研究设计与样本

  • 多中心回顾性研究,纳入269例符合IPAF标准的患者。
  • 按MSA和MAA存在与否对IPAF患者进行分层,并与IIM-ILD、IPF及非IIM CTD-ILD队列比较。
  • 主要终点为3年无移植生存率。

主要发现

  • 269例IPAF患者中,35例(13%)携带MSA,65例(24.2%)携带MAA。
  • MSA阳性IPAF患者生存率最高,接近IIM-ILD患者。
  • MAA阳性IPAF与无MSA/MAA的IPAF患者生存无差异。
  • UIP形态与不同结局风险相关,非UIP形态IPAF患者生存接近非IIM CTD-ILD。

临床怎么用

  • 对符合IPAF标准的患者应检测MSA,MSA阳性者宜按IIM-ILD进行管理。
  • 在IPAF患者中评估UIP形态有助于判断结局风险。

局限性

  • 回顾性研究设计可能存在选择偏倚和信息偏倚。
  • IPAF为研究性分类标准,缺乏明确的治疗推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interstitial pneumonia with autoimmune features (IPAF) characterises individuals with interstitial lung disease (ILD) and features of connective tissue disease (CTD) who fail to satisfy CTD criteria. Inclusion of myositis-specific antibodies (MSAs) in the IPAF criteria has generated controversy, as these patients also meet proposed criteria for an antisynthetase syndrome. Whether MSAs and myositis-associated antibodies (MAA) identify phenotypically distinct IPAF subgroups remains unclear.A multicentre, retrospective investigation was conducted to assess clinical features and outcomes in patients meeting IPAF criteria stratified by the presence of MSAs and MAAs. IPAF subgroups were compared to cohorts of patients with idiopathic inflammatory myopathy-ILD (IIM-ILD), idiopathic pulmonary fibrosis and non-IIM CTD-ILDs. The primary end-point assessed was 3-year transplant-free survival.269 patients met IPAF criteria, including 35 (13%) with MSAs and 65 (24.2%) with MAAs. Survival was highest among patients with IPAF-MSA and closely approximated those with IIM-ILD. Survival did not differ between IPAF-MAA and IPAF without MSA/MAA cohorts. Usual interstitial pneumonia (UIP) morphology was associated with differential outcome risk, with IPAF patients with non-UIP morphology approximating survival observed in non-IIM CTD-ILDs. MSAs, but not MAAs identified a unique IPAF phenotype characterised by clinical features and outcomes similar to IIM-ILD. UIP morphology was a strong predictor of outcome in others meeting IPAF criteria.Because IPAF is a research classification without clear treatment approach, these findings suggest that MSAs should be removed from the IPAF criteria and such patients should be managed as an IIM-ILD.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Graham J, Bauer Ventura I, Newton CA, et al. Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype. Eur Respir J. 2020. PMID: 32675203. doi:10.1183/13993003.01205-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。